NCT05001971 2026-01-15
Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy
Hunan Cancer Hospital
Phase 2 Completed
Clinical Trials
6 trialsNCT06341530 2024-04-02
Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT06048315 2023-09-21
A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody
Qianfoshan Hospital
Phase 3 Not yet recruiting
NCT05485350 2022-08-03
Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)
Peking University Third Hospital
Phase 2 Unknown
NCT05460481 2022-07-20
Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors
Hunan Cancer Hospital
Phase 2 Unknown
NCT05319886 2022-05-20
AP
The First Affiliated Hospital of Xinxiang Medical College
Unknown